MCID: PRK024
MIFTS: 50

Parkinson Disease, Juvenile, Type 2 malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Mental diseases, Metabolic diseases

Aliases & Classifications for Parkinson Disease, Juvenile, Type 2

About this section

Aliases & Descriptions for Parkinson Disease, Juvenile, Type 2:

Name: Parkinson Disease, Juvenile, Type 2 49 11
Parkinson Disease 2 45 67 24
Park2 10 45 67
Autosomal Recessive Juvenile Parkinson Disease 45 67
Early-Onset Parkinson Disease 45 51
Young-Onset Parkinson Disease 45 51
Pdj 45 67
Autosomal Recessive Early-Onset Parkinson Disease Type 2 67
Chromosome 6-Linked Autosomal Recessive Parkinsonism 67
Parkinsonism, Early Onset, with Diurnal Fluctuation 45
 
Parkinson Disease Autosomal Recessive, Early Onset 45
Parkinson Disease 2, Autosomal Recessive Juvenile 65
Early-Onset Parkinsonism with Diurnal Fluctuation 67
Autosomal Recessive Juvenile Parkinson Disease 2 10
Parkinsonism Young Adult Onset 67
Parkinsonism, Juvenile 65
Juvenile Parkinsonism 45
Yopd 51
Epdf 67
Jp 45

Characteristics:

Orphanet epidemiological data:

51
early-onset parkinson disease:
Inheritance: Autosomal dominant,Autosomal recessive; Prevalence: 1-5/10000 (Europe); Age of onset: Adult; Age of death: elderly

HPO:

61
parkinson disease, juvenile, type 2:
Onset and clinical course: adult onset
Inheritance: autosomal recessive inheritance


Classifications:



External Ids:

OMIM49 600116
Disease Ontology10 DOID:0060368
Orphanet51 2828
ICD10 via Orphanet28 G20
MedGen34 C1868675
MeSH36 D020734
UMLS65 C1868675, C0752105

Summaries for Parkinson Disease, Juvenile, Type 2

About this section
UniProtKB/Swiss-Prot:67 Parkinson disease 2: A neurodegenerative disorder characterized by bradykinesia, rigidity, postural instability, tremor, and onset usually before 40. It differs from classic Parkinson disease by early DOPA-induced dyskinesia, diurnal fluctuation of the symptoms, sleep benefit, dystonia and hyper-reflexia. Dementia is absent. Pathologically, patients show loss of dopaminergic neurons in the substantia nigra, similar to that seen in Parkinson disease; however, Lewy bodies (intraneuronal accumulations of aggregated proteins) are absent.

MalaCards based summary: Parkinson Disease, Juvenile, Type 2, also known as parkinson disease 2, is related to parkinson disease 6, early onset and parkinson disease 1, and has symptoms including substantia nigra gliosis, postural instability and bradykinesia. An important gene associated with Parkinson Disease, Juvenile, Type 2 is PARK2 (Parkin RBR E3 Ubiquitin Protein Ligase), and among its related pathways are Pink/Parkin Mediated Mitophagy and Alpha-synuclein signaling. Affiliated tissues include kidney, liver and prostate, and related mouse phenotypes are integument and cardiovascular system.

Disease Ontology:10 A Parkinson's disease caused by mutation in the parkin gene, PARK2, on chromosome 6q25.2-q27.

Description from OMIM:49 600116

Related Diseases for Parkinson Disease, Juvenile, Type 2

About this section

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 7, Autosomal Recessive Early-Onset Parkinson Disease 6, Early Onset
Parkinson Disease 19, Juvenile-Onset Parkinson Disease 10
Parkinson Disease 16 Parkinson Disease 13
Parkinson Disease 11 Parkinson Disease 21
Parkinson Disease 18 Parkinson Disease 5
Parkinson Disease 4 Parkinson Disease 1
parkinson disease, juvenile, type 2 Parkinson Disease 8
Parkinson Disease 17 Parkinson Disease 20, Early-Onset
Parkinson Disease 15, Autosomal Recessive Parkinson Disease 14, Autosomal Recessive
Parkinson Disease 12 Lrrk2-Related Parkinson Disease
Parkinson Disease Type 3 Parkinson Disease Type 9
Dnajc6-Related Parkinson Disease Eif4g1-Related Parkinson Disease
Gigyf2-Related Parkinson Disease Pla2g6-Related Parkinson Disease
Synj1-Related Parkinson Disease Fbxo7-Related Parkinson Disease
Htra2-Related Parkinson Disease Park7-Related Parkinson Disease
Snca-Related Parkinson Disease Vps35-Related Parkinson Disease
Hereditary Late-Onset Parkinson Disease

Diseases related to Parkinson Disease, Juvenile, Type 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 81)
idRelated DiseaseScoreTop Affiliating Genes
1parkinson disease 6, early onset30.7LRRK2, PARK2, PARK7, PINK1
2parkinson disease 130.3LRRK2, PARK2, PARK7, SNCA
3essential tremor29.9HTRA2, LRRK2, PARK2, SNCA
4parkinson disease, late-onset29.4LRRK2, PACRG, PARK2, PARK7, PINK1, SNCA
5pink1 type of young-onset parkinson disease12.4
6atypical juvenile parkinsonism11.9
7polyposis, juvenile intestinal11.6
8juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome11.4
9leprosy11.4
10lung cancer11.4
11multiple system atrophy11.0
12dementia11.0
13dementia, lewy body11.0
14epilepsy, progressive myoclonic 2b11.0
15supranuclear palsy, progressive11.0
16synucleinopathy11.0
17paratyphoid fever11.0
18movement disease11.0
19tauopathy11.0
20parkin type of early-onset parkinson disease11.0
21tremor11.0
22ovarian cancer, somatic10.9
23rapp-hodgkin syndrome10.9
24muscular dystrophy, limb-girdle, type 2h10.9
25parkinson disease 810.9
26dementia, frontotemporal10.9
27angelman syndrome10.9
28johanson-blizzard syndrome10.9
29amyotrophic lateral sclerosis-parkinsonism/dementia complex10.9
30fanconi anemia, complementation group a10.9
31parkinson disease 15, autosomal recessive10.9
32multifocal dystonia10.9
33bell's palsy10.9
34snca-related parkinson disease10.9
35hypersomnia10.9
36central nervous system disease10.7
37nervous system disease10.7
38colorectal cancer10.5
39chronic interstitial cystitis10.0
40back pain9.9SNCA, UCHL1
41cardiomyopathy, dilated, 1u9.9SNCA, UCHL1
42glioma susceptibility 19.9
43iron-refractory iron deficiency anemia9.9PARK2, PARK7, SNCA
44angelman syndrome due to a point mutation9.9LRRK2, SNCA
45esophagus carcinoma in situ9.8LRRK2, SNCA
46renal cell carcinoma9.8
47attention deficit-hyperactivity disorder9.8
48leukemia9.8
49autism spectrum disorder9.8
50lymphoblastic leukemia9.8

Graphical network of the top 20 diseases related to Parkinson Disease, Juvenile, Type 2:



Diseases related to parkinson disease, juvenile, type 2

Symptoms for Parkinson Disease, Juvenile, Type 2

About this section

Symptoms by clinical synopsis from OMIM:

600116

Clinical features from OMIM:

600116

HPO human phenotypes related to Parkinson Disease, Juvenile, Type 2:

(show all 9)
id Description Frequency HPO Source Accession
1 substantia nigra gliosis HP:0011960
2 postural instability HP:0002172
3 bradykinesia HP:0002067
4 rigidity HP:0002063
5 hyperreflexia HP:0001347
6 tremor HP:0001337
7 dystonia HP:0001332
8 parkinsonism HP:0001300
9 gait disturbance HP:0001288

UMLS symptoms related to Parkinson Disease, Juvenile, Type 2:


bradykinesia, tremor, muscle rigidity

Drugs & Therapeutics for Parkinson Disease, Juvenile, Type 2

About this section

Drugs for Parkinson Disease, Juvenile, Type 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Bromocriptineapproved, investigationalPhase 22925614-03-331101
Synonyms:
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione
(5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman
(5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
(6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione
2-Bromo-alpha-ergocryptine
2-Bromo-alpha-ergokryptin
2-Bromo-alpha-ergokryptine
2-Bromoergocryptine Methanesulfonate
2-Bromoergokryptine
2-bromo-α-ergocryptine
2-bromo-α-ergokryptin
2-bromo-α-ergokryptine
22260-51-1 (mesylate (salt))
25614-03-3
AC-13601
AC1L1KXS
AC1Q2716
Alti-Bromocriptine
Apo-Bromocriptine
BIDD:GT0464
BPBio1_001131
BRD-K14496212-001-01-1
Bagren
Biomol-NT_000005
Bromergocryptine
Bromocriptin
Bromocriptina
Bromocriptina [INN-Spanish]
Bromocriptine
Bromocriptine (USAN/INN)
Bromocriptine Methanesulfonate
Bromocriptine [BAN]
Bromocriptine [USAN:BAN:INN]
 
Bromocriptine methanesulfonate
Bromocriptinum
Bromocriptinum [INN-Latin]
Bromocryptin
Bromocryptine
Bromoergocriptine
Bromoergocryptine
C06856
C32H40BrN5O5
CB-154
CCRIS 3244
CHEBI:3181
CHEMBL493
CID31101
Cycloset
D03165
DB01200
EINECS 247-128-5
Ergocryptine, 2-bromo- (8CI)
Ergoset
LS-64540
Lopac0_000171
MolPort-002-512-064
NCGC00024584-04
NCI60_001365
NSC169774
PDSP2_001500
Parlodel
Parlodel Snaptabs
Prestwick0_000121
Prestwick1_000121
Prestwick2_000121
SPBio_002101
UNII-3A64E3G5ZO
bromocriptine
nchembio873-comp18
2
DopamineapprovedPhase 2308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
3Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 29988
4Neurotransmitter AgentsPhase 214795
5HormonesPhase 211748
6Hormone AntagonistsPhase 210002
7Antiparkinson AgentsPhase 21312
8Dopamine AgentsPhase 23084
9Dopamine AgonistsPhase 2544
10Insulin, Globin Zinc4278
11insulin4278

Interventional clinical trials:

idNameStatusNCT IDPhase
1Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 DiabetesRecruitingNCT02544321Phase 2
2Mutations Associated With Parkinson s DiseaseCompletedNCT01547832
3Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)RecruitingNCT00104585
4Hereditary Parkinson s Disease Natural History ProtocolRecruitingNCT02511015
5Parkinson's Families ProjectRecruitingNCT02760108
6Genetic Study in Young Onset Parkinson's DiseaseActive, not recruitingNCT01529970
7Proof of Concept BeatParkNot yet recruitingNCT02647242

Search NIH Clinical Center for Parkinson Disease, Juvenile, Type 2

Genetic Tests for Parkinson Disease, Juvenile, Type 2

About this section

Anatomical Context for Parkinson Disease, Juvenile, Type 2

About this section

MalaCards organs/tissues related to Parkinson Disease, Juvenile, Type 2:

33
Kidney, Liver, Prostate, Pituitary, Myeloid, Endothelial, Breast

Animal Models for Parkinson Disease, Juvenile, Type 2 or affiliated genes

About this section

MGI Mouse Phenotypes related to Parkinson Disease, Juvenile, Type 2:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00107718.0HTRA2, LRRK2, PARK2, SNCA, UCHL1
2MP:00053857.4HTRA2, LRRK2, PARK2, PINK1, SNCA, UCHL1
3MP:00053867.1HTRA2, LRRK2, PARK2, PARK7, PINK1, SNCA
4MP:00036317.0HTRA2, LRRK2, PARK2, PARK7, PINK1, SNCA

Publications for Parkinson Disease, Juvenile, Type 2

About this section

Variations for Parkinson Disease, Juvenile, Type 2

About this section

UniProtKB/Swiss-Prot genetic disease variations for Parkinson Disease, Juvenile, Type 2:

67 (show all 28)
id Symbol AA change Variation ID SNP ID
1PARK2p.Val15MetVAR_019733
2PARK2p.Arg33GlnVAR_019734
3PARK2p.Pro37LeuVAR_019735rs148990138
4PARK2p.Arg42ProVAR_019736
5PARK2p.Ala46ProVAR_019737
6PARK2p.Ala82GluVAR_019738rs55774500
7PARK2p.Ala92ValVAR_019739
8PARK2p.Lys161AsnVAR_019741
9PARK2p.Lys211AsnVAR_019744
10PARK2p.Lys211ArgVAR_019745
11PARK2p.Cys212TyrVAR_019746
12PARK2p.Thr240MetVAR_019747
13PARK2p.Thr240ArgVAR_019748
14PARK2p.Arg256CysVAR_019750rs150562946
15PARK2p.Arg275TrpVAR_019752rs34424986
16PARK2p.Gly284ArgVAR_019754
17PARK2p.Cys289GlyVAR_019755rs55961220
18PARK2p.Gly328GluVAR_019756
19PARK2p.Arg334CysVAR_019757
20PARK2p.Thr351ProVAR_019759
21PARK2p.Thr415AsnVAR_019763
22PARK2p.Gly430AspVAR_019764
23PARK2p.Cys431PheVAR_019765
24PARK2p.Pro437LeuVAR_019766rs149953814
25PARK2p.Cys441ArgVAR_019767
26PARK2p.Val56GluVAR_070078
27PARK2p.Arg402CysVAR_070079
28PARK2p.Cys418ArgVAR_070080

Clinvar genetic disease variations for Parkinson Disease, Juvenile, Type 2:

5 (show all 22)
id Gene Variation Type Significance SNP ID Assembly Location
1PODXLNM_005397.3(PODXL): c.89_90insGTCGCCCCinsertionLikely pathogenicrs759639123GRCh37Chr 7, 131241029: 131241030
2PARK2NM_004562.2(PARK2): c.1292G> T (p.Cys431Phe)single nucleotide variantPathogenicrs397514694GRCh37Chr 6, 161771237: 161771237
3PARK2NM_004562.2(PARK2): c.172-?_871+?deldeletionPathogenicGRCh37Chr 6, 162206804: 162683797
4PARK2NM_004562.2(PARK2): c.413-?_534+?deldeletionPathogenicGRCh37Chr 6, 162622163: 162622284
5PARK2NM_004562.2(PARK2): c.719C> G (p.Thr240Arg)single nucleotide variantPathogenicrs137853054GRCh37Chr 6, 162394349: 162394349
6PARK2NM_004562.2(PARK2): c.931C> T (p.Gln311Ter)single nucleotide variantPathogenicrs137853055GRCh37Chr 6, 161990389: 161990389
7PARK2NM_004562.2(PARK2): c.245C> A (p.Ala82Glu)single nucleotide variantPathogenicrs55774500GRCh37Chr 6, 162683724: 162683724
8PARK2NM_004562.2(PARK2): c.8-?_171+?deldeletionPathogenicGRCh37Chr 6, 162864342: 162864505
9PARK2NM_004562.2(PARK2): c.872-?_1083+?deldeletionPathogenicGRCh37Chr 6, 161969886: 161990448
10PARK2NM_004562.2(PARK2): c.1358G> A (p.Trp453Ter)single nucleotide variantPathogenicrs137853056GRCh37Chr 6, 161771171: 161771171
11PARK2NM_004562.2(PARK2): c.483A> T (p.Lys161Asn)single nucleotide variantPathogenicrs137853057GRCh37Chr 6, 162622214: 162622214
12PARK2PARK2, 1-BP DEL, 202AdeletionPathogenic
13PARK2NM_004562.2(PARK2): c.735-?_871+?deldeletionPathogenicGRCh37Chr 6, 162206804: 162206940
14PARK2NM_004562.2(PARK2): c.635G> A (p.Cys212Tyr)single nucleotide variantPathogenicrs137853058GRCh37Chr 6, 162394433: 162394433
15PARK2NM_004562.2(PARK2): c.167T> A (p.Val56Glu)single nucleotide variantPathogenicrs137853059GRCh37Chr 6, 162864346: 162864346
16PARK2PARK2, 1-BP DEL, 255AdeletionPathogenic
17PARK2NM_004562.2(PARK2): c.823C> T (p.Arg275Trp)single nucleotide variantPathogenicrs34424986GRCh37Chr 6, 162206852: 162206852
18PARK2NM_004562.2(PARK2): c.633A> T (p.Lys211Asn)single nucleotide variantPathogenicrs137853060GRCh37Chr 6, 162394435: 162394435
19PARK2PARK2, 1-BP DEL, 1072TdeletionPathogenic
20NM_004562.2(PARK2): c.7+1G> Tsingle nucleotide variantPathogenicrs397518439GRCh37Chr 6, 163148693: 163148693
21PARK2NM_004562.2(PARK2): c.719C> T (p.Thr240Met)single nucleotide variantPathogenicrs137853054GRCh37Chr 6, 162394349: 162394349
22PARK2PARK2, EX5-6 DELdeletionPathogenic

Expression for genes affiliated with Parkinson Disease, Juvenile, Type 2

About this section
Search GEO for disease gene expression data for Parkinson Disease, Juvenile, Type 2.

Pathways for genes affiliated with Parkinson Disease, Juvenile, Type 2

About this section

GO Terms for genes affiliated with Parkinson Disease, Juvenile, Type 2

About this section

Cellular components related to Parkinson Disease, Juvenile, Type 2 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1mitochondrial outer membraneGO:000574110.0PINK1, VPS13C
2axonGO:00304249.2LRRK2, PARK7, SNCA
3mitochondrionGO:00057399.0LRRK2, PARK7, VPS13C

Biological processes related to Parkinson Disease, Juvenile, Type 2 according to GeneCards Suite gene sharing:

(show all 35)
idNameGO IDScoreTop Affiliating Genes
1regulation of protein ubiquitinationGO:003139610.3PARK2, PINK1
2positive regulation of mitochondrial fissionGO:009014110.3PARK2, PINK1
3regulation of synaptic vesicle transportGO:190280310.3PARK2, PINK1
4cellular response to toxic substanceGO:009723710.3PARK2, PINK1
5negative regulation of reactive oxygen species metabolic processGO:200037810.2PARK2, PINK1
6negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathwayGO:190338410.2PARK7, PINK1
7activation of protein kinase B activityGO:003214810.2PARK7, PINK1
8positive regulation of mitochondrial electron transport, NADH to ubiquinoneGO:190295810.2PARK7, PINK1
9negative regulation of oxidative stress-induced cell deathGO:190320210.2PARK7, PINK1
10regulation of reactive oxygen species metabolic processGO:200037710.2PARK2, PINK1
11macroautophagyGO:001623610.1PARK2, PINK1
12positive regulation of sequence-specific DNA binding transcription factor activityGO:005109110.1PARK7, PINK1
13dopamine uptake involved in synaptic transmissionGO:005158310.1PARK2, SNCA
14mitophagyGO:000042210.1PARK2, PINK1
15negative regulation of hydrogen peroxide-induced cell deathGO:190320610.1LRRK2, PARK7
16regulation of neurotransmitter secretionGO:004692810.0PARK2, SNCA
17cellular response to dopamineGO:190335110.0LRRK2, PARK2
18positive regulation of protein kinase B signalingGO:005189710.0PARK7, PINK1
19regulation of canonical Wnt signaling pathwayGO:006082810.0LRRK2, PARK2
20protein localization to mitochondrionGO:007058510.0LRRK2, PARK2
21negative regulation of neuron deathGO:190121510.0PARK7, SNCA
22negative regulation of autophagosome assemblyGO:19029029.9LRRK2, PINK1
23negative regulation of cell deathGO:00605489.9PARK2, PARK7
24positive regulation of peptidyl-serine phosphorylationGO:00331389.9PARK7, SNCA
25regulation of neuron deathGO:19012149.9LRRK2, SNCA
26phosphorylationGO:00163109.7LRRK2, PINK1
27peptidyl-serine phosphorylationGO:00181059.5LRRK2, PINK1
28regulation of mitophagyGO:19031469.4HTRA2, PARK2, PINK1
29synaptic transmission, dopaminergicGO:00019639.3PARK2, PARK7, SNCA
30response to oxidative stressGO:00069799.2LRRK2, PARK2, PARK7
31negative regulation of protein phosphorylationGO:00019339.1LRRK2, PARK2, PARK7
32adult locomotory behaviorGO:00083449.0HTRA2, PARK7, SNCA
33cellular protein catabolic processGO:00442579.0HTRA2, PARK2
34cellular response to oxidative stressGO:00345998.7HTRA2, LRRK2, PARK7, PINK1
35mitochondrion organizationGO:00070057.9HTRA2, LRRK2, PARK2, PARK7, PINK1, VPS13C

Molecular functions related to Parkinson Disease, Juvenile, Type 2 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1alpha-tubulin bindingGO:00430149.4PACRG, SNCA

Sources for Parkinson Disease, Juvenile, Type 2

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet